VIDA Insights
VIDAProduct specifications |
Information source:
Vendor
Last updated: Feb. 28, 2020 |
General | |
---|---|
Product name | VIDA Insights |
Company | VIDA |
Subspeciality | Chest |
Modality | CT |
Disease targeted | COPD, interstitial lung disease (ILD), emphysema, COVID-19 |
Key-features | Lung disease biomarkers, lung (lobe) volume quantification, scan suitability quality check, Hyperion View (tMPR), low density tissue quantification by lobe, high density tissue quantification by lobe, trachea analysis and quanitification |
Suggested use | Before: stratifying reading process (non, single, double read) During: perception aid (prompting all abnormalities/results/heatmaps), report suggestion |
Data characteristics | |
Population | All Chest CT scans |
Input | Non-contrast |
Input format | DICOM |
Output | Quantified Values, Novel Visualizations, Quick Flag Diagrams |
Output format | DICOM SC |
Technology | |
Integration | Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform |
Deployment | Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based |
Trigger for analysis | Automatically, right after the image acquisition |
Processing time | 1 - 10 minutes |
Certification | |
CE
|
Certified,
Class IIa
, MDD
|
FDA
|
510(k) cleared, Class II |
Market presence | |
On market since | 12-2019 |
Distribution channels | Nuance, Eureka Clinical AI, TeraRecon, IBM Watson Health, Blackford, Intelerad |
Countries present (clinical, non-research use) | |
Paying clinical customers (institutes) | |
Research/test users (institutes) | |
Pricing | |
Pricing model | Subscription |
Based on | Total imaging volume |
Evidence | |
Peer reviewed papers on performance | |
Non-peer reviewed papers on performance | |
Other relevant papers |
|